Why the study?
Nadroparin is commonly used off-label in neonates and infants to prevent thromboembolic events, but the recommended dosing regimen often fails to achieve therapeutic targets.
Does the current therapeutic dosage of nadroparin achieve target anti-Xa levels in neonates and infants under 8 months?
Does the current therapeutic dosage of nadroparin achieve target anti-Xa levels in neonates and infants under 8 months?
Current therapeutic doses of nadroparin (150-200 IU/kg q12 h) in neonates and infants under 8 months may result in subtherapeutic exposure, suggesting higher doses are required to achieve target anti-Xa levels.
May inform nadroparin dosing adjustments in neonates via population PK modeling; hypothesis-generating and requires prospective validation before practice change.
Objectives: Nadroparin, a low-molecular-weight-heparin is commonly used off-label in neonates and infants for thromboembolic events prevention. However, the recommended dosing regimen often fails to achieve therapeutic target ranges. This study aimed to develop a population pharmacokinetic (PK) model of nadroparin to determine an appropriate dosing regimen for neonates and infants less than 8 months. Methods: A retrospective chart review was conducted on patients treated with nadroparin at Children’s Hospital of Fudan University between July 2021 and December 2023. A population PK model was developed using anti-Xa levels, and its predictive performance was evaluated internally. Monte Carlo simulations were performed to design an initial dosing schedule targeting anti-Xa levels between 0.5 and 1 IU/mL. Results: A total of 40 neonates and infants aged less than 8 months with gestational age ranging from 25 to 41 weeks treated with nadroparin were enrolled in the study for analysis. A one-compartment PK model with first order absorption and elimination was adequately fitted to the data. Creatinine clearance was identified as a significant factor contributing to inter-individual variability in clearance. The typical population parameter estimates of clearance, distribution volume and absorption rate in this population were 0.211 L/h, 1.55 L and 0.495 h -1 , respectively. Our findings suggest that current therapeutic doses of nadroparin (150–200 IU/kg q12 h) may result in subtherapeutic exposure, thus higher doses might be required. Conclusion: The present study offers the first estimation of PK parameters for nadroparin in preterm or term neonates and infants less than 8 months utilizing the model. Our findings have potential implications for recommending initial personalized dosages, particularly among patient populations exhibiting similar characteristics.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: